Amanta Healthcare revenue rises 5% in Q1FY27 as SteriPort expansion delays
Amanta Healthcare delivered stable Q1FY27 results with ₹69 crore revenue and 22% EBITDA margin, navigating polymer price volatility through strategic pricing. The company faces a short-term delay in SteriPort Line 3 commissioning to August 2026 but maintains strong growth prospects with SVP facility launch in Q4FY27. Long-term projections indicate peak revenue of ₹425 crore in FY28 with improved margins driven by operating leverage and captive solar power savings.
*this image is generated using AI for illustrative purposes only.
Amanta Healthcare Limited reported a resilient financial performance for the quarter ended June 30, 2026, with revenue from operations rising by approximately 5% year-on-year to ₹69 crore. Despite facing inflationary pressures and a temporary spike in polymer raw material costs driven by geopolitical tensions, the company maintained a healthy EBITDA margin of roughly 22%, translating to an EBITDA of about ₹15 crore. The stable profitability underscores the effectiveness of management’s operational discipline and price realization strategies during a period characterized by broader business slowdowns.
The primary driver of the current quarter’s cost pressure was not merely raw material volatility but also the absorption of overheads related to upcoming capacity expansions. Bhavesh Patel, Chairman and Managing Director, noted that manpower and other operating costs were incurred in anticipation of the SteriPort Line 3 commissioning, which was delayed by one quarter due to civil construction activities. Consequently, these overheads were absorbed without corresponding revenue contribution from the new line during Q1FY27. Paras Mehta, Chief Financial Officer, added that while polymer prices surged by 70-80% for two months, the impact was mitigated through price corrections, with selling prices increased by approximately ₹1.50 per unit against an input cost rise of ₹2.25.
Capacity Expansion and Timelines
Amanta Healthcare is currently executing significant capacity expansions aimed at enhancing its sterile dosage form portfolio. The SteriPort platform, which contributes around 44% of total revenue, is being expanded from 6.6 crore bottles per year to roughly 12 crore bottles per year. This expansion targets high-value therapies including oncology, critical care, anesthetics, and pediatrics. Although originally targeted for Q1FY27, the commercial production of SteriPort Line 3 has been shifted to the last week of August 2026, following FDA plan approvals on August 5, 2026. Validation and qualification activities are expected to conclude by August 18, 2026.
Simultaneously, the company is advancing its Small Volume Parenteral (SVP) facility, which focuses on export-centric products such as inhalation solutions, ophthalmics, and preservative-free unit doses. The SVP business contributed around 20% of FY26 revenue. Management expects this new facility to commence operations in Q4FY27, specifically between February and March 2027, following Factory Acceptance Testing (FAT) scheduled for November 2026 in the USA. Unlike the SteriPort project, the SVP facility requires minimal civil work, reducing timeline speculation.
| Project | Total Capex (₹ Cr) | Capex Spent (₹ Cr) | Expected Commissioning | Key Focus |
|---|---|---|---|---|
| SteriPort Line 3 | 90 | 80 | Aug 2026 | High-value therapies, India market |
| SVP Facility | 30 | 7 | Feb-Mar 2027 | Inhalation, Ophthalmics, Exports |
Financial Outlook and Margins
Looking ahead, management projects that the full utilization of SteriPort Line 3 will contribute approximately ₹70 crore to the top line over the remaining seven months of FY27. For FY28, with both SteriPort and SVP capacities live, peak revenue potential is estimated at roughly ₹425 crore. EBITDA margins are expected to expand to 25-26% in FY28, driven by operating leverage from the new lines and cost savings from a 10.8 MW captive solar power plant commissioned in June 2026. The solar project is expected to save approximately ₹75 lakh per month, contributing to an overall EBITDA margin expansion of 4-5% when combined with the operational efficiencies of SteriPort Line 3.
Depreciation expenses are set to increase by approximately ₹6 crore annually compared to FY26, due to the new SteriPort line, SVP facility, and solar plant. Interest costs are projected at ₹21 crore for FY27 and ₹18-19 crore for FY28, reflecting a gradual reduction in debt despite additional borrowing for the solar captive project. The effective tax rate is expected to remain at 26%. Working capital days remain elevated at 141 days for FY26, primarily due to mandatory quarantine periods for export shipments, which can extend up to 25-30 days.
Strategic Growth Drivers
Beyond capacity expansion, Amanta Healthcare is strengthening its formulation development capabilities to support its SVP portfolio. A dedicated team of five scientists is working on a pipeline of 20 products, with one inhalation product expected to be commercialized by mid-September 2026. The long-term vision remains focused on sterile dosage forms, with plans to explore new packaging materials beyond plastic, such as glass, and to enter advanced regulated markets in the UK, EU, Australia, and Canada. The incremental Return on Capital Employed (ROCE) for SteriPort Line 3 is estimated at 16-17%, while the SVP facility is projected to yield 14-15% ROCE, positioning the company competitively within the industry.
Historical Stock Returns for Amanta Healthcare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.98% | +27.74% | +18.92% | +85.65% | +38.12% | +38.12% |
How will the delayed commissioning of SteriPort Line 3 impact Amanta Healthcare's ability to meet the projected ₹70 crore revenue contribution for the remainder of FY27?
What specific regulatory hurdles or market entry strategies is the company employing to successfully penetrate advanced regulated markets like the UK, EU, and Canada with its new SVP portfolio?
Given the elevated working capital days of 141 due to export quarantine periods, what operational changes or supply chain optimizations are planned to improve cash conversion cycles in FY28?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
